Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERVFree Report) by 1.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 369,670 shares of the company’s stock after purchasing an additional 6,626 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.58% of Verve Therapeutics worth $5,153,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Daiwa Securities Group Inc. boosted its holdings in Verve Therapeutics by 35.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,772 shares of the company’s stock valued at $94,000 after acquiring an additional 1,759 shares during the period. International Assets Investment Management LLC purchased a new position in Verve Therapeutics during the 4th quarter valued at about $97,000. China Universal Asset Management Co. Ltd. boosted its holdings in Verve Therapeutics by 437.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,815 shares of the company’s stock valued at $123,000 after acquiring an additional 7,174 shares during the period. Merit Financial Group LLC purchased a new position in Verve Therapeutics during the 3rd quarter valued at about $151,000. Finally, Teacher Retirement System of Texas boosted its holdings in Verve Therapeutics by 10.8% during the 3rd quarter. Teacher Retirement System of Texas now owns 12,058 shares of the company’s stock valued at $160,000 after acquiring an additional 1,174 shares during the period. 97.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on VERV. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of Verve Therapeutics in a research note on Wednesday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Verve Therapeutics in a research note on Thursday, May 9th. Finally, Stifel Nicolaus decreased their price objective on Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

View Our Latest Stock Report on Verve Therapeutics

Insiders Place Their Bets

In other news, insider Andrew D. Ashe purchased 76,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average price of $6.26 per share, with a total value of $475,760.00. Following the completion of the transaction, the insider now directly owns 342,509 shares in the company, valued at approximately $2,144,106.34. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 19.30% of the stock is currently owned by corporate insiders.

Verve Therapeutics Stock Up 1.2 %

VERV stock opened at $5.25 on Tuesday. The business has a 50 day moving average price of $7.19 and a 200 day moving average price of $11.05. The stock has a market cap of $440.79 million, a price-to-earnings ratio of -1.83 and a beta of 1.86. Verve Therapeutics, Inc. has a fifty-two week low of $4.90 and a fifty-two week high of $21.42.

Verve Therapeutics (NASDAQ:VERVGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.11. The company had revenue of $5.70 million for the quarter, compared to analyst estimates of $2.11 million. Verve Therapeutics had a negative return on equity of 37.35% and a negative net margin of 1,226.51%. The company’s revenue for the quarter was up 305.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.73 EPS for the current year.

Verve Therapeutics Profile

(Free Report)

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

Featured Articles

Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERVFree Report).

Institutional Ownership by Quarter for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.